What's New in Therapy for Male Androgenetic Alopecia?

This study found an association between finasteride use and increased reporting of suicidality and depression in young patients with androgenetic alopecia, potentially mediated by sexual dysfunction.

In this real-world study, low-level laser helmet therapy for androgenetic alopecia showed that male patients with specific scalp conditions may have better results after more than 180 uses or a year of treatment.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This study reported 14 cases of frontal edema following mesotherapy for androgenetic alopecia, suggesting clinicians should be aware of this potential side effect.

This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.

In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This study found that low-dose oral minoxidil for androgenetic alopecia was associated with a higher incidence of hypertrichosis and edema compared to previous studies, but it remains a generally well-tolerated treatment option.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This article describes the characteristics and management of hypertrichosis induced by low-dose oral minoxidil used for hair disorders, but reports no new clinical findings.

This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

This study evaluated oral dutasteride for male androgenetic alopecia in a real-world setting, reporting that it effectively improved hair conditions in 90% of patients using monotherapy, with a good safety profile, particularly at low doses.

In this correspondence, researchers reported that very-low-dose oral minoxidil (0.25 mg/d) showed some effectiveness in stabilizing trichoscopic parameters in male androgenetic alopecia. However, their analysis suggests that higher doses (2.5–5 mg/d) may lead to better clinical responses with similar rates of adverse events.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study found that platelet-rich plasma combined with other hair restoration therapies significantly increased hair density in patients with androgenetic alopecia, though it did not statistically affect hair shaft diameter.

This study found that low-level laser therapy may reduce inflammation and increase hair thickness in patients with lichen planopilaris after six months of treatment, though the small sample size limits the findings.

This review discusses the use of platelet-rich plasma in dermatology for various applications such as tissue regeneration and wound healing, but it reports no new clinical results and calls for clearer guidance on suitable treatments.

This study found that topical cetirizine 1% significantly improved hair density and diameter in patients with androgenetic alopecia, with patients tolerating the treatment well.

Combining platelet-rich plasma with 5% minoxidil solution improves hair regrowth in androgenetic alopecia patients.

Results are not reported in this letter to the editor on the use of scalp threading with polydioxanone monofilament threads for hair restoration.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.

This study observed that autologous platelet-rich plasma treatment improved hair count and density in areas with androgenetic alopecia compared to placebo, with differing outcomes based on the PRP collection device used.

In this pilot study, botulinum toxin was found to be a safe and effective treatment for androgenetic alopecia in most participants, though larger studies are needed to confirm these findings.

This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.

This review concluded that FDA-cleared low-level laser therapy devices are safe and effective for patients with male and female pattern hair loss who do not respond to or tolerate standard treatments.

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

This study found that oral minoxidil 5 mg daily significantly improves hair growth in men with androgenetic alopecia, although common side effects include hypertrichosis and pedal edema.

This study found that a combination of topical minoxidil and finasteride helped maintain hair density in patients with androgenetic alopecia after initial oral finasteride treatment.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This article includes no new results; it discusses ongoing treatment approaches for frontal fibrosing alopecia and lichen planopilaris.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study found that low-level light therapy significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, suggesting it could be an effective treatment option.

This study concluded that mesotherapy with a dutasteride-containing solution was the most effective option for treating androgenetic alopecia in males, promoting hair growth and reducing hair loss.

This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.

This study found that mesotherapy with a dutasteride-containing preparation improved hair growth indicators in female pattern hair loss better than saline, with minimal side effects and greater effectiveness in patients with shorter disease duration.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.

This review explores the current understanding of genetic and hormonal influences on male androgenetic alopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

This study found that the HairMax LaserComb® significantly increased hair density and was safe and well tolerated for treating androgenetic alopecia in men compared to a sham device.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This article reviews the historical developments in understanding and treating male pattern hair loss, emphasizing the role of dihydrotestosterone and 5α-reductase inhibitors, but reports no new clinical findings.

FPHL affects hair density and diameter, causing visible hair loss in older women.

This study reported that a 0.005% finasteride solution may encourage hair regrowth and reduce balding areas in patients with androgenic alopecia, without significant absorption or adverse effects.